Tags

Type your tag names separated by a space and hit enter

Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis.
Diagn Pathol 2010; 5:75DP

Abstract

BACKGROUND

We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance.

METHOD

We studied the expressions of CK7, CK20, MUC1, MUC2, MUC5AC, and MUC6 in 43 patients with ACs. Clinical data were obtained retrospectively by examining surgically resected ACs of the patients.

RESULTS

We classified the cases into 3 groups: tumors expressing CK20 and lacking MUC1 (intestinal type [I-type], 26%), tumors expressing MUC1 and lacking CK20 (pancreatobiliary type [PB-type], 35%), and those expressing or lacking both CK20 and MUC1 (other type [O-type], 39%). Eight (73%) of 11 I-type carcinomas, 3 (20%) of 15 PB-type carcinomas, and 4 (24%) of 17 O-type carcinomas were classified as pT1. The number of I-type carcinomas in the early tumor stages was significantly higher than the number of PB- and O-type carcinomas (p = 0.014 and p = 0.018, respectively). The 5-year survival rates for pT1, pT2, and pT3 tumors were 76%, 33%, and 22%, respectively (p < 0.001). Rates of MUC5AC and MUC6 coexpression for I-type, PB-type, and O-type tumors were 18%, 13%, and 53%, respectively. There was a significant correlation between MUC5AC and MUC6 coexpression and O-type characteristics (p = 0.031). The five-year survival rates for O-type ACs with and without MUC5AC and MUC6 coexpression were 71% and 17%, respectively (p = 0.048).

CONCLUSIONS

The immunohistochemical subtypes based on CK and MUC expression correlated with tumor progression. Gastric MUC5AC and MUC6 coexpression correlated with better prognosis for O-type ACs.

Authors+Show Affiliations

Department of Digestive and General Surgery, Shimane University Faculty of Medicine,89-1 Enyacho, Izumo, Shimane 693-8501, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21106111

Citation

Kawabata, Yasunari, et al. "Cytokeratin 20 (CK20) and Apomucin 1 (MUC1) Expression in Ampullary Carcinoma: Correlation With Tumor Progression and Prognosis." Diagnostic Pathology, vol. 5, 2010, p. 75.
Kawabata Y, Tanaka T, Nishisaka T, et al. Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. Diagn Pathol. 2010;5:75.
Kawabata, Y., Tanaka, T., Nishisaka, T., Inao, T., Nishi, T., & Yano, S. (2010). Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. Diagnostic Pathology, 5, p. 75. doi:10.1186/1746-1596-5-75.
Kawabata Y, et al. Cytokeratin 20 (CK20) and Apomucin 1 (MUC1) Expression in Ampullary Carcinoma: Correlation With Tumor Progression and Prognosis. Diagn Pathol. 2010 Nov 25;5:75. PubMed PMID: 21106111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. AU - Kawabata,Yasunari, AU - Tanaka,Tsuneo, AU - Nishisaka,Takashi, AU - Inao,Touko, AU - Nishi,Takeshi, AU - Yano,Seiji, Y1 - 2010/11/25/ PY - 2010/09/11/received PY - 2010/11/25/accepted PY - 2010/11/26/entrez PY - 2010/11/26/pubmed PY - 2011/5/25/medline SP - 75 EP - 75 JF - Diagnostic pathology JO - Diagn Pathol VL - 5 N2 - BACKGROUND: We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance. METHOD: We studied the expressions of CK7, CK20, MUC1, MUC2, MUC5AC, and MUC6 in 43 patients with ACs. Clinical data were obtained retrospectively by examining surgically resected ACs of the patients. RESULTS: We classified the cases into 3 groups: tumors expressing CK20 and lacking MUC1 (intestinal type [I-type], 26%), tumors expressing MUC1 and lacking CK20 (pancreatobiliary type [PB-type], 35%), and those expressing or lacking both CK20 and MUC1 (other type [O-type], 39%). Eight (73%) of 11 I-type carcinomas, 3 (20%) of 15 PB-type carcinomas, and 4 (24%) of 17 O-type carcinomas were classified as pT1. The number of I-type carcinomas in the early tumor stages was significantly higher than the number of PB- and O-type carcinomas (p = 0.014 and p = 0.018, respectively). The 5-year survival rates for pT1, pT2, and pT3 tumors were 76%, 33%, and 22%, respectively (p < 0.001). Rates of MUC5AC and MUC6 coexpression for I-type, PB-type, and O-type tumors were 18%, 13%, and 53%, respectively. There was a significant correlation between MUC5AC and MUC6 coexpression and O-type characteristics (p = 0.031). The five-year survival rates for O-type ACs with and without MUC5AC and MUC6 coexpression were 71% and 17%, respectively (p = 0.048). CONCLUSIONS: The immunohistochemical subtypes based on CK and MUC expression correlated with tumor progression. Gastric MUC5AC and MUC6 coexpression correlated with better prognosis for O-type ACs. SN - 1746-1596 UR - https://www.unboundmedicine.com/medline/citation/21106111/Cytokeratin_20__CK20__and_apomucin_1__MUC1__expression_in_ampullary_carcinoma:_Correlation_with_tumor_progression_and_prognosis_ L2 - https://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-5-75 DB - PRIME DP - Unbound Medicine ER -